Lv22
140 积分 2024-06-12 加入
Mantle cell lymphoma: 2017 update on diagnosis, risk‐stratification, and clinical management
3天前
已完结
Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index
21天前
已完结
Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial
21天前
已完结
Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation
28天前
已完结
Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation
28天前
已关闭
Behind the scenes of non‐nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, TP53 pathway and mutated status of immunoglobulin heavy chain genes
28天前
已完结
Treatment approaches for patients with TP53-mutated mantle cell lymphoma
28天前
已完结
Recent advances in genomics and therapeutics in mantle cell lymphoma
28天前
已完结
How I manage mantle cell lymphoma: indolent versus aggressive disease
28天前
已完结
Frontline Treatment of Mantle Cell Lymphoma
29天前
已完结
皖公网安备34019202002308
